Literature DB >> 12639164

Warfarin and amoxicillin/clavulanate drug interaction.

Liya Davydov1, Marina Yermolnik, Lewis J Cuni.   

Abstract

OBJECTIVE: To report a case of warfarin-amoxicillin/clavulanate potassium (AM/CL) interaction resulting in an elevated international normalized ratio (INR) and hematuria. CASE
SUMMARY: A 58-year-old Hawaiian/Asian/European woman developed an elevated INR and microscopic hematuria as a result of a drug-drug interaction between warfarin and AM/CL. DISCUSSION: Our report of an increased INR with bleeding complications as a result of an interaction between warfarin and AM/CL is consistent with those in the literature. Although the mechanism for this interaction is not fully known, it is suspected that a decrease in vitamin K-producing gut flora with resulting vitamin K deficiency would be the most likely contributing factor. An objective causality assessment revealed that this adverse drug event as a result of the warfarin and AM/CL interaction was possible.
CONCLUSIONS: An increased INR secondary to warfarin interactions with various antibacterial agents is a known phenomenon. An increased awareness of warfarin-AM/CL interaction and appropriate monitoring are essential to control the INR levels and prevent bleeding complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639164     DOI: 10.1345/aph.1C243

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  9 in total

1.  Warfarin-flucloxacillin interaction presenting as cardioembolic ischemic stroke.

Authors:  Aine Merwick; Niamh Hannon; Peter J Kelly; Killian O'Rourke
Journal:  Eur J Clin Pharmacol       Date:  2010-03-05       Impact factor: 2.953

2.  Non-traumatic compartment syndrome secondary to deep vein thrombosis and anticoagulation.

Authors:  Peter Alexander Newman; Sunny Deo
Journal:  BMJ Case Rep       Date:  2014-01-17

3.  Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial.

Authors:  Qian Zhang; Guy Simoneau; Celine Verstuyft; Ludovic Drouet; Claire Bal dit Sollier; Jean-Claude Alvarez; Nathalie Rizzo-Padoin; Jean Francois Bergmann; Laurent Becquemont; Stéphane Mouly
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

4.  Interaction of antibiotics and warfarin in pediatric cardiology patients.

Authors:  M C Johnson; M Wood; V Vaughn; L Cowan; A M Sharkey
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

5.  Antagonistic effects of simultaneous exposure of ergot alkaloids on kidney adenosine triphosphatase system.

Authors:  Ali S Moubarak; Zelpha B Johnson; Charles F Rosenkrans
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Sep-Oct       Impact factor: 2.416

6.  Factors influencing warfarin response in hospitalized patients.

Authors:  Mahmoud I Abdel-Aziz; Mostafa A Sayed Ali; Ayman K M Hassan; Tahani H Elfaham
Journal:  Saudi Pharm J       Date:  2015-02-27       Impact factor: 4.330

7.  Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area.

Authors:  Xolani W Njovane; Pius S Fasinu; Bernd Rosenkranz
Journal:  Cardiovasc J Afr       Date:  2013-03       Impact factor: 1.167

8.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

9.  Acute warfarin toxicity: An unanticipated consequence of amoxicillin/clavulanate administration.

Authors:  Timothy R Larsen; Alehegn Gelaye; Christopher Durando
Journal:  Am J Case Rep       Date:  2014-01-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.